Tesetaxel as Second-line Therapy for Patients With Advanced Gastric Cancer

Phase 2 Unknown 27 enrolled Genta Incorporated

NaSingle-groupOpen-labelTreatment

Summary

Tesetaxel is an orally administered chemotherapy agent of the taxane class. This study is being undertaken to evaluate the efficacy and safety of tesetaxel administered as second-line therapy to patients with advanced gastric cancer.

Timeline

Start: 2010-03
Primary completion: 2012-09
Completion: 2012-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tesetaxel	Small molecule	35 mg/m2	Oral
Subject	Tesetaxel	Small molecule	40 mg	Oral
Subject	Tesetaxel	Small molecule	50 mg	Oral

Tesetaxel as Second-line Therapy for Patients With Advanced Gastric Cancer

Summary

Timeline

Drugs

Indications